AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 11/02/21

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $0.20 (+25.0% Y/Y) and the consensus Revenue Estimate is $544.08M (+4.8% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 88%...

Reinforcing its commitment to purpose-driven strategy, performance, and culture Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020 data...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethas...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. East...

Biopharmaceuticals company Bristol Myers Squibb’s (BMY) strong clinical and operational performance and continued momentum across its product portfolio helped it generate robust revenue growth in its last reported quarter. But given that its stock price has dipped recently, is now an o...

According to a recent report from MarketsAndMarkets.com, the global Parkinson’s disease treatment market is expected to reach $5.69 billion by 2022, growing from $4.24 billion in 2017, expanding at a CAGR of 6.1%.  The report notes that this market is being driven by rising geriat...

The pharmaceutical industry’s increased focus on developing better treatments for many of today's most complex diseases should help it to grow for the foreseeable future. However, because highly priced pharma stocks are susceptible to anticipated market volatility in the near term, we ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2021. The presentation will begin at 1:15 PM Eastern Time and a live webcast will ...

- Study was successful in demonstrating statistically significant improvement in efficacy for IPX-203 compared to immediate-release CD/LD, even when IPX-203 was dosed on average three times per day and immediate-release CD/LD was dosed on average five times per day - New Drug Applic...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m. ET. The upcoming event will feature members of Amneal’s management team as well as Alberto Espay, MD, MSc, FAAN, FAN...